Sanochemia - European patent granted for Vidon® in Photodynamic Therapy

Sanochemia Pharmazeutika AG, Vienna (ISIN AT0000776307, ISIN DE000A1G7JQ9), announces that the European Patent Office positively completed the examination procedure for the patent application of Vidon® in Photodynamic Therapy (PDT) of bladder cancer.

Vidon® (PVP-Hypericin) is being developed as a game changing technology in the management of bladder cancer. The patent covers the treatment of bladder cancer with the PVP-Hypericin formulation developed by SANOCHEMIA. The patent will protect Vidon® in PDT until 2035.

"The positive decision of the European Patent Office and the US patent which was granted in 2018 are an important basis for SANOCHEMIA for the further development and the long-term value of Vidon®." Christina Abrahamsberg, CSO.

Bladder cancer is the most common malignancy of the urinary tract. Approximately 75% of initially diagnosed bladder cancers are non-muscle invasive tumors, which means that the tumor is restricted to the mucosa. In 30-80% of the patients, recurrences occur, requiring repeated surgeries. About 45% of bladder cancers will progresses to a muscle-invasive bladder carcinoma.

Early detection, timely and appropriate treatment are therefore essential factors for improving the prognosis of urinary bladder carcinoma patients.  

Photodynamic therapy (PDT) is a method of treating bladder tumors with a photosensitizer and light. The method is based on the selective accumulation of the photosensitizer in malignant cells and the irradiation of the tumor tissue with light of a specific wavelength. Subsequently, photochemical processes generate toxic substances that specifically damage the tumor.

Vidon® is developed by Sanochemia Pharmazeutika AG as a diagnostic and therapeutic option for patients with non-muscle invasive bladder cancer.